Johnson & Johnson (JNJ) Q3 2022 Earnings Call Transcript

Oct. 18, 2022 9:52 AM ETJohnson & Johnson (JNJ)
SA Transcripts profile picture
SA Transcripts

Johnson & Johnson (NYSE:JNJ) Q3 2022 Earnings Conference Call October 18, 2022 8:30 AM ET

Company Participants

Jessica Moore - Vice President, Investor Relations

Joe Wolk - Executive Vice President, Chief Financial Officer

Thibaut Mongon - Executive Vice President & Worldwide Chairman, Consumer Health

Ashley McEvoy - Executive Vice President, Worldwide Chairman, MedTech

Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals

Conference Call Participants

Chris Schott - JPMorgan

Larry Biegelsen - Wells Fargo

Louise Chen - Cantor Fitzgerald

Joshua Jennings - Cowen

Joanne Wuensch - Citi

Geoff Meacham - Bank of America

Terence Flynn - Morgan Stanley


Good morning and welcome to Johnson & Johnson's Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. [Operator Instructions]

I will now turn the conference call over to Johnson & Johnson. You may begin.

Unidentified Company Representative

Please note that today's meeting may include forward-looking statements relating to, among other things, the company's future financial performance, product development, market position, and business strategy and the anticipated separation of the company's Consumer Health business.

You're cautioned not to rely on these statements, which are based on current expectations of future events, using the information available as of today's date, and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected.

In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic. A further description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2021 Form 10-K, which is available at and on the SEC's website.

Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.